Pegilodecakin for metastatic kidney cancer

Combinations of immunotherapy and vascular endothelial growth factor (VEGF) inhibitors have been proven to effective at improving survival for people with advanced or metastatic renal cell carcinoma (RCC). However, the role of a cytokine called interleukin-10 (IL-10) has been shown to enhance immunotherapy-induced anti-cancer activity. In this phase 1 trial, the safety, tolerability and preliminary […]

read more
Showing the single result
  TOP